Transfusion and Apheresis Science
Volume 28, Issue 1 , Pages 71-80 , February 2003

Extracorporeal photochemotherapy for graft versus host disease in pediatric patients

  • Justyna Kanold

      Affiliations

    • Unité Bioclinique de Thérapie Cellulaire, Service d’Hématologie et d’Oncologie Pédiatrique, Hôtel Dieu, C.H.U., B.P.69, 11, Boulevard Léon Malfreyt 63003 Clermont-Ferrand, France
    • Service d’Hématologie et d’Oncologie Pédiatrique, C.H.U. Clermont-Ferrand, France
    • Corresponding Author InformationCorresponding author. Tel.: +33-4-73-75-00-09; fax: +33-4-73-75-00-59
    • ,
  • Catherine Paillard

      Affiliations

    • Service d’Hématologie et d’Oncologie Pédiatrique, C.H.U. Clermont-Ferrand, France
    • ,
  • Pascale Halle

      Affiliations

    • Unité Bioclinique de Thérapie Cellulaire, Service d’Hématologie et d’Oncologie Pédiatrique, Hôtel Dieu, C.H.U., B.P.69, 11, Boulevard Léon Malfreyt 63003 Clermont-Ferrand, France
    • ,
  • Michel D’Incan

      Affiliations

    • Service de Dermatologie, C.H.U. Clermont-Ferrand, France
    • ,
  • Pierre Bordigoni

      Affiliations

    • Unité de Transplantation Médullaire, Médecine Infantile 2, C.H.U. Nancy, France
    • ,
  • François Deméocq

      Affiliations

    • Unité Bioclinique de Thérapie Cellulaire, Service d’Hématologie et d’Oncologie Pédiatrique, Hôtel Dieu, C.H.U., B.P.69, 11, Boulevard Léon Malfreyt 63003 Clermont-Ferrand, France
    • Service d’Hématologie et d’Oncologie Pédiatrique, C.H.U. Clermont-Ferrand, France

References 

  1. Ringden O. Allogeneic bone marrow transplantation for hematological malignancies-controversies and recent advances. Acta Oncol. 1997;36:549–564
  2. Peters C, Minkov M, Gadner H, Klingebiel T, Vossen J, Locatelli F, et al. For the European Group for Blood and marrow Transplantation (EBMT) Working Party Paediatric Diseases and the International BFM Study Group-Subcommittee Bone Marrow Transplantation (IBFM-SG). Statement of current majority practices in graft-versus-host disease prophylaxis and treatment in children. Bone Marrow Transpl 2000;26:405–411
  3. Sullivan KM, Witherspoon RP, Storb R, Deeg HJ, Dahlberg S, Sandres JE, et al.  Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-versus-host disease. Blood. 1988;72:555–561
  4. Vogelsang GB. How I treat graft-versus-host disease?. Blood. 2001;97:1196–1201
  5. Vogelsang GB, Farmer ER, Hess AD, Altamonte V, Beschorner WE, Jabs DA, et al.  Thalidomide for the treatment of chronic graft-versus-host disease. New Engl. J. Med. 1992;326:1055–1058
  6. Eppinger T, Ehninger G, Steinfert M, Niethammer D, Dopfer R. 8-Methoxypsoralen and ultraviolet A therapy for cutaneous manifestations of graft-versus-host disease. Transplant. 1990;50:807–811
  7. Vogelsang G, Wolff D, Altomonte V, Farmer E, Morison WL, Corio R, et al.  Treatment of chronic graft-versus-host disease with ultraviolet irradiation and psoralen (PUVA). Bone Marrow Transpl. 1996;7:1061–1067
  8. Hervé P, Wijdenes J, Bergerat JP, Bordigoni P, Milpied N, Cahn JY, et al.  Treatment of corticoid resistant acute graft-versus-host disease by in vivo administration of antiinterleukin-2 receptor monoclonal antibody (B-B10). Blood. 1990;75:1017–1023
  9. Herbelin C, Stephan JL, Donadieu J, Le deist F, Racadot E, Wijdenes J, et al.  Treatment of steroid resistant acute graft-versus-host disease with an anti-IL-2 receptor monoclonal antibody (BT563) in children who received T cell-depleted, partially matched, related bone marrow transplants. Bone Marrow Transpl. 1994;13:563–569
  10. Przepiorka D, Kernan NA, Ippoliti C, Papadopoulos EB, Giralt S, Khouri I, et al.  Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood. 2000;95:83–89
  11. Mookerjee B, Altomonte V, Vogelsang G. Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus. Bone Marrow Transpl. 1999;24:517–520
  12. Kanamaru A, Takemoto Y, Kakishita E, Dony H, Kodera Y, Moriyama Y, et al.  FK506 treatment of graft-versus-host disease developing or exacerbating during prophylaxis and therapy with cyclosporin and/or other immunosuppressants. Japanese FK506 BMT Study Group. Bone Marrow Transpl. 1995;15:885–889
  13. Greinix HT, Volc-Platzer B, Kalhs P, Fisher G, Rosenmayr A, Keil F, et al.  Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: a pilot study. Blood. 2000;96:2426–2431
  14. Greinix HT, Volc-Platzer B, Rabitsch W, Gmeinhart B, Guevara-Pineda C, Kalhs P, et al.  Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Blood. 1998;92:3098–3104
  15. Owsianowski M, Gollnick H, Siegert W, Schwerdtfeger R, Orfanos CE. Successful treatment of severe chronic graft-versus-host disease with extracorporeal photopheresis. Bone Marrow Transpl. 1994;14:845–848
  16. Bladon J, Taylor PC. Extracorporeal photopheresis induces apoptosis in the lymphocytes of cutaneous T-cell lymphoma and graft-versus-host disease patients. Br. J. Haem. 1999;107:707–711
  17. Sniecinski I. Extracorporeal photochemotherapy: a scientific overview. Transfus Sci. 1994;15:429–434
  18. Zic JA, Miller JL, Stricklin GP, King LE. The North American experience with photopheresis. Ther. Apher. 1999;3:50–62
  19. Child FJ, Ratnavel R, Watkins P, Samson D, Apperley J, Ball J, et al.  Extracorporeal photopheresis in the treatment of chronic graft-versus-host disease. Bone Marrow Transpl. 1999;23:881–887
  20. Rossetti F, Zulian F, Dall’Arnico R, et al.  Extracorporeal photochemotherapy as single therapy for extensive, cutaneous, chronic graft-versus-host disease. Transplantation. 1995;59:149–151
  21. Rossetti F, Dall’Amico R, Crovetti G, Messina C, Montini G, Dini G, et al.  Extracorporeal photochemistry for the treatment of graft-versus-host disease. Bone Marrow Transpl. 1996;18:175–181
  22. Dall’Amico R, Rossetti F, Zulian F, Montini G, Murer L, Andreetta L, et al.  Photopheresis in paediatric patients with drug-resistant chronic graft-versus-host disease. Br. J. Haematol. 1997;97:848–854
  23. Perotti C, Torreta L, Viarengo G, Roveda L, Bernuzzi S, Carbone S, et al.  Feasibility and safety of a new technique of extracorporeal photochemotherapy: experience of 240 procedures. Haematologica. 1999;84:237–241
  24. Halle P, Paillard C, D’Incan M, Bordigoni P, Piguet C, De Lumley L, et al.  Successful extracorporeal photochemotherapy for chronic graft-versus-host disease in pediatric patients. J. Hematother. Stem Cell Res. 2002;11(3):501–512
  25. D’incan M, Kanold J, Halle P, De Lumley L, Souteyrand P, Demeocq F. Extracorporeal photopheresis as an alternative therapy for drug-resistant graft versus host disease: three cases. Ann. Dermatol. Venereol. 2000;127(2):166–170
  26. Salvaneschi L, Perotti C, Zecca M, Bernuzzi S, Viarengo G, Giorgiani G, et al.  Extracorporeal photochemotherapy for treatment of acute and chronic GVHD in childhood. Transfusion. 2001;41(10):1299–1305
  27. Looks A, Fuchs D, Rulke D, Lange D, Zintl F, Wollina U. Successful treatment of acute graft versus host disease after bone marrow transplantation in 16-year-old girl with extracorporeal photopheresis. Onkologie. 1997;20:340–342
  28. Balda B, Kostantinov A, Starz H, Gneklow A, Heidemann P. Extracorporeal photochemotherapy as an effective treatment modality in chronic graft versus host disease. J. Eur. Acad. Dermatol. Venerol. 1996;7:155–162
  29. Besnier DP, Chabannes D, Mahe B, Mussini JM, Baranger TA, Muller JY, et al.  Treatment of graft-versus-host disease by extracorporeal photochemotherapy: a pilot study. Transplantation. 1997;64(1):49–54
  30. Biagi E, Perseghin P, Buscemi F, Dassi M, Rovelli A, Balduzzi A. Effectiveness of extracorporeal photochemotherapy in treating refractory chronic graft-versus-host disease. Haematologica. 2000;85(3):329–330
  31. Perutelli P, Rivabella L, Lanino E, Pistoia V, Dini G. ATP downregulation in mononuclear cells from children with graft-versus-host disease following extracorporeal photochemotherapy. Haematologica. 2002;87(3):335–336
  32. Perseghin P, Dassi M, Balduzzi A, Rovelli A, Bonanomi S, Uderzo C. Mononuclear cell collection in patients undergoing extra-corporeal photo-chemotherapy for acute and chronic graft vs host disease: comparison between Cobe Spectra version 4.7 and 6.0 (Auto PBSC). J. Clin. Apher. 2002;17:65–71
  33. Glucksbera H, Storb R, Fefer A, et al.  Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation. 1974;18:295–304
  34. Shulman HM, Sullivan KNI, Weiden PL, et al.  Chronic graft-versus-host syndrome in man. A long-term clinico-pathologic study of 20 Seattle patients. Am J Med. 1980;69:204–217
  35. Kanold J, Halle P, Rapatel C, Berger M, Gembara P, deLumley L, et al.  Safe and efficient peripheral blood stem cell collection in the smallest of children. Ther. Apher. 1998;2(1):49–57
  36. Andreu G, Leon A, Heshmati F, Tod M, Menkes CJ, Baudelot J, et al.  Extracorporeal photochemotherapy: evaluation of two techniques and use in connective tissue disorders. Transf. Sci. 1994;15:443–454
  37. Locatelli F, Percivalle E, Comoli P, et al.  Human cytomegalovirus infection in pediatric patients given allogeneic bone marrow transplantation: role of early treatment of antigenemia on patients’ outcome. Br. J. Haematol. 1994;88:64–71
  38. Schooneman F, Claise C. Treatment of graft versus host disease by photopheresis?. Transfus Sci. 1996;17(4):527–536

PII: S1473-0502(02)00102-7

doi: 10.1016/S1473-0502(02)00102-7

Transfusion and Apheresis Science
Volume 28, Issue 1 , Pages 71-80 , February 2003

Article Tools